Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy.

Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy.

IMPORTANCE: Neuromyelitis optica (NMO) is an inflammatory disease of the optic nerves and spinal cord that leads to blindness and paralysis. Effective immunosuppression is the standard of care for relapse prevention. OBJECTIVE: To compare the relapse and treatment failure rates among patients receiv...

Bibliografiset tiedot
Päätekijät:	Mealy, M, Wingerchuk, D, Palace, J, Greenberg, B, Levy, M
Aineistotyyppi:	Journal article
Kieli:	English
Julkaistu:	2014

Samankaltaisia teoksia

Treatment of Neuromyelitis Optica: Review and Recommendations.
Tekijä: Kimbrough, D, et al.
Julkaistu: (2012)

Treatment of neuromyelitis optica: Review and recommendations
Tekijä: Kimbrough, D, et al.
Julkaistu: (2012)

Neuromyelitis optica relapses: race and rate, immunosuppression and impairment
Tekijä: Tackley, G, et al.
Julkaistu: (2016)

TREATMENT OF NEUROMYELITIS OPTICA WITH AZATHIOPRINE
Tekijä: Elsone, L, et al.
Julkaistu: (2012)

B-Cell Targeted Treatments for Neuromyelitis Optica Spectrum Disorder: A Focus on CD19 and CD20
Tekijä: Levy M, et al.
Julkaistu: (2021-08-01)

Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers.
Tekijä: Palace, J, et al.
Julkaistu: (2010)

Seasonal pattern of variation in neuromyelitis optica relapses
Tekijä: Elsone, L, et al.
Julkaistu: (2012)

A practical guide to the treatment of neuromyelitis optica.
Tekijä: Palace, J, et al.
Julkaistu: (2012)

A single relapse induces worsening of disability and health-related quality of life in patients with neuromyelitis optica spectrum disorder
Tekijä: Achim Berthele, et al.
Julkaistu: (2023-04-01)

Prognosis of Relapsing Neuromyelitis Optica
Tekijä: J Gordon Millichap
Julkaistu: (2003-03-01)

Relapsing neuromyelitis optica spectrum disorder
Tekijä: M Lakshmi Lavanya, et al.
Julkaistu: (2021-01-01)

The borderland of neuromyelitis optica.
Tekijä: Matthews, L, et al.
Julkaistu: (2009)

Good response to Ofatumumab in a child with severe relapsing Neuromyelitis Optica
Tekijä: Sedani, S, et al.
Julkaistu: (2012)

Racial differences in neuromyelitis optica spectrum disorder
Tekijä: Kim, S, et al.
Julkaistu: (2018)

Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials.
Tekijä: Kitley, J, et al.
Julkaistu: (2014)

Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials
Tekijä: Kitley, J, et al.
Julkaistu: (2014)

Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder.
Tekijä: Pittock, S, et al.
Julkaistu: (2019)

Use of mitoxantrone in neuromyelitis optica.
Tekijä: Kitley, J, et al.
Julkaistu: (2011)

Treatment strategies for neuromyelitis optica
Tekijä: Tzu-Lun Huang, et al.
Julkaistu: (2018-01-01)

Magnetic resonance imaging in neuromyelitis optica.
Tekijä: Tackley, G, et al.
Julkaistu: (2014)

Antibodies to aquaporin-1 are not present in neuromyelitis optica
Tekijä: Waters, P, et al.
Julkaistu: (2015)

Observation of the efficacy of ofatumumab in the treatment of neuromyelitis optica spectrum disorders
Tekijä: ZHANG Rui, et al.
Julkaistu: (2024-06-01)

Efficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorder
Tekijä: Bo Chen, et al.
Julkaistu: (2017-04-01)

Advances in the long-term treatment of neuromyelitis optica spectrum disorder
Tekijä: Monique Anderson, et al.
Julkaistu: (2024-01-01)

The evolving clinical spectrum of neuromyelitis optica
Tekijä: Viegas, S, et al.
Julkaistu: (2008)

Clinical evaluation of rituximab treatment for neuromyelitis optica
Tekijä: M.J. Fernández-Megía, et al.
Julkaistu: (2015-10-01)

The role of imaging in diagnosing neuromyelitis optica spectrum disorder
Tekijä: Matthews, L, et al.
Julkaistu: (2014)

Neuroimmunology: towards more-accurate diagnosis in neuromyelitis optica.
Tekijä: Fujihara, K, et al.
Julkaistu: (2014)

The role of imaging in diagnosing neuromyelitis optica spectrum disorder
Tekijä: Matthews, L, et al.
Julkaistu: (2013)

Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica
Tekijä: Waters, P, et al.
Julkaistu: (2016)

Treatment response, risk of relapse and clinical characteristics of Taiwanese patients with neuromyelitis optica spectrum disorder
Tekijä: Yi-Hong Liu, et al.
Julkaistu: (2022-09-01)

Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.
Tekijä: Collongues, N, et al.
Julkaistu: (2013)

Relapse of Neuromyelitis Optica Spectrum Disorder Associated with Intravenous Lidocaine
Tekijä: Akiyuki Uzawa, et al.
Julkaistu: (2011-01-01)

Seasonality of 278 neuromyelitis optica relapses in a Brazilian cohort
Tekijä: Denis Bernardi Bichuetti, et al.
Julkaistu: (2015-02-01)

Review: Treatment of neuromyelitis optica: Current debate
Tekijä: Tomoko Okamoto, et al.
Julkaistu: (2008-07-01)

Treatment of neuromyelitis optica: an evidence based review
Tekijä: Douglas Sato, et al.
Julkaistu: (2012-01-01)

Current and future treatment approaches for neuromyelitis optica
Tekijä: Nicolas Collongues, et al.
Julkaistu: (2011-03-01)

A mathematical model of cellular swelling in Neuromyelitis optica
Tekijä: Laranjeira, S, et al.
Julkaistu: (2017)

Neuromyelitis Optica
Tekijä: Goyal V, et al.
Julkaistu: (2009-10-01)

Neuromyelitis optica
Tekijä: Jacob Anu, et al.
Julkaistu: (2007-01-01)